Wall Street analysts tracking OraSure Technologies generally issue neutral or hold ratings rather than strong buy or sell recommendations. Proponents highlight the company's strong cash position, innovative sample collection portfolio (such as DNA Genotek), and emergency-use authorizations as positive catalysts. Conversely, conservative investors point to ongoing net losses and shifting diagnostic market volumes as factors requiring careful risk evaluation.